N4 Pharma PLC Change of Auditor
23 Agosto 2024 - 4:30AM
RNS Regulatory News
RNS Number : 5818B
N4 Pharma PLC
23 August 2024
23 August 2024
N4 Pharma
plc
("N4 Pharma" or the
"Company")
Change of
Auditor
N4 Pharma Plc (AIM: N4P), the
specialist pharmaceutical company developing Nuvec®, a novel
delivery system for cancer treatments, gene therapy and vaccines,
announces that it has appointed Gravita II LLP as the Company's
auditor.
In accordance with section 519 of
the Companies Act 2006, the previous auditor, Saffery LLP, has
deposited with the Company a statement confirming that there are no
matters to be brought to the attention of the Company's members or
creditors.
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive
Director
Engage with us directly at N4 Pharma
Investor Hub
To hear more, visit
|
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe
(Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob
Rees (Corporate Broking)
|
Tel: +44(0)20 3470 0470
|
|
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
|
Tel: +44(0)20 3657 0050
|
|
|
|
About N4 Pharma
N4 Pharma is a specialist
pharmaceutical company developing a novel delivery system for
oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec® and Liptide, a unique
peptide/lipid delivery system via its subsidiary
Nanogenics.
N4 Pharma's business model is to
partner with companies developing products in these fields to use
Nuvec® or Liptide® as the delivery vehicle for these products. As
these products progress through pre‐clinical and clinical programs,
N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the
market.
For further information on the Company
visit www.n4pharma.com or sign up at investors.n4pharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPPJMRTMTBTMAI
N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
